AP2369A - Carbonylamino pyrrolopyrazoles, potent kinase inhibitors. - Google Patents

Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.

Info

Publication number
AP2369A
AP2369A AP2008004506A AP2008004506A AP2369A AP 2369 A AP2369 A AP 2369A AP 2008004506 A AP2008004506 A AP 2008004506A AP 2008004506 A AP2008004506 A AP 2008004506A AP 2369 A AP2369 A AP 2369A
Authority
AP
ARIPO
Prior art keywords
pyrrolopyrazoles
carbonylamino
kinase inhibitors
potent kinase
potent
Prior art date
Application number
AP2008004506A
Other languages
English (en)
Other versions
AP2008004506A0 (en
Inventor
Liming Dong
Chuangxing Guo
Yufeng Hong
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP2008004506A0 publication Critical patent/AP2008004506A0/xx
Application granted granted Critical
Publication of AP2369A publication Critical patent/AP2369A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AP2008004506A 2005-12-21 2006-12-12 Carbonylamino pyrrolopyrazoles, potent kinase inhibitors. AP2369A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75334905P 2005-12-21 2005-12-21
US86493206P 2006-11-08 2006-11-08
PCT/IB2006/003646 WO2007072153A2 (en) 2005-12-21 2006-12-12 Carbonylamino pyrrolopyrazoles, potent kinase inhibitors

Publications (2)

Publication Number Publication Date
AP2008004506A0 AP2008004506A0 (en) 2008-06-30
AP2369A true AP2369A (en) 2012-02-29

Family

ID=38189022

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2008004506A AP2369A (en) 2005-12-21 2006-12-12 Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.

Country Status (26)

Country Link
US (1) US7884117B2 (es)
EP (1) EP1979356B1 (es)
JP (1) JP4635089B2 (es)
KR (1) KR101029167B1 (es)
AP (1) AP2369A (es)
AU (1) AU2006327866B2 (es)
BR (1) BRPI0620354A2 (es)
CA (1) CA2634381C (es)
CR (1) CR10094A (es)
CU (1) CU23751B7 (es)
DK (1) DK1979356T3 (es)
EA (1) EA015513B1 (es)
EC (1) ECSP088558A (es)
ES (1) ES2435405T3 (es)
GE (1) GEP20104974B (es)
HR (1) HRP20130976T1 (es)
IL (1) IL191776A (es)
MA (1) MA30076B1 (es)
ME (1) ME00006B (es)
MY (1) MY151455A (es)
NO (1) NO20082482L (es)
NZ (1) NZ568692A (es)
PL (1) PL1979356T3 (es)
PT (1) PT1979356E (es)
RS (2) RS20080281A (es)
WO (1) WO2007072153A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL385265A1 (pl) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
BRPI0923225A2 (pt) 2008-12-02 2016-10-04 Chiralgen Ltd metodo para sintese de acidos nucleicos modificados no atomo de fosforo
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
DK2620428T3 (da) * 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
BR112013012175A2 (pt) 2010-11-17 2019-09-24 Hoffmann La Roche combinação, coadministração, uso e método
US8771682B2 (en) 2011-04-26 2014-07-08 Technische Universtität Dresden Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
CN107365339A (zh) 2011-07-19 2017-11-21 波涛生命科学有限公司 合成官能化核酸的方法
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
HK1200093A1 (en) 2012-03-16 2015-07-31 霍夫曼-拉罗奇有限公司 Methods of treating melanoma with pak1 inhibitors
DK2872147T3 (da) 2012-07-13 2023-02-20 Wave Life Sciences Ltd Fremgangsmåde til fremstilling af kirale oligonukleotider
SG11201500243WA (en) 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
EP3094728B1 (en) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chiral design
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10131679B2 (en) 2014-10-31 2018-11-20 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole compound
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
AU2016281225B2 (en) * 2015-06-15 2020-10-15 Ube Corporation Substituted dihydropyrrolopyrazole derivative
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017144546A1 (en) 2016-02-23 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
JP7530297B2 (ja) 2018-11-14 2024-08-07 Ｕｂｅ株式会社 ジヒドロピロロピラゾール誘導体
CN113164477A (zh) 2018-12-14 2021-07-23 达纳-法伯癌症研究所股份有限公司 C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途
EP3902542A4 (en) * 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. CYCLIN DEPENDENT KINASE 7 INHIBITORS AND USES THEREOF
WO2020212484A1 (en) 2019-04-17 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2025078334A1 (en) 2023-10-09 2025-04-17 Institut National de la Santé et de la Recherche Médicale Combination of pak1 inhibitors and clk inhibitors for preventing resistance to chemotherapy in patients suffering from acute myeloid leukemia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012242A2 (en) * 2000-08-10 2002-02-14 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004056827A2 (en) * 2002-12-19 2004-07-08 Pharmacia Italia Spa Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
WO2005030776A1 (en) * 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05000945A (es) 2002-07-25 2005-05-16 Pharmacia Italia Spa Biciclo-pirazoles activos como inhibidores de la cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
GB0229526D0 (en) 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
CA2593428C (en) 2005-01-10 2012-04-17 Pfizer Inc. Pyrrolopyrazoles, potent kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012242A2 (en) * 2000-08-10 2002-02-14 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004056827A2 (en) * 2002-12-19 2004-07-08 Pharmacia Italia Spa Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
WO2005030776A1 (en) * 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors

Also Published As

Publication number Publication date
US7884117B2 (en) 2011-02-08
MA30076B1 (fr) 2008-12-01
EA015513B1 (ru) 2011-08-30
JP4635089B2 (ja) 2011-02-16
MEP0808A (xx) 2010-02-10
AU2006327866B2 (en) 2012-06-14
DK1979356T3 (da) 2013-11-18
PT1979356E (pt) 2013-11-21
EA200801291A1 (ru) 2008-12-30
KR101029167B1 (ko) 2011-04-12
ES2435405T3 (es) 2013-12-19
RS53029B (sr) 2014-04-30
JP2009520805A (ja) 2009-05-28
WO2007072153A8 (en) 2008-08-14
CU20080115A7 (es) 2010-08-30
RS20080281A (sr) 2009-09-08
NO20082482L (no) 2008-07-02
ME00006B (me) 2010-02-10
US20090318440A1 (en) 2009-12-24
WO2007072153A3 (en) 2007-10-25
IL191776A0 (en) 2008-12-29
EP1979356B1 (en) 2013-09-18
CA2634381C (en) 2011-03-08
AU2006327866A1 (en) 2007-06-28
KR20080080567A (ko) 2008-09-04
CR10094A (es) 2008-08-01
EP1979356A2 (en) 2008-10-15
HK1128290A1 (en) 2009-10-23
GEP20104974B (en) 2010-04-26
NZ568692A (en) 2011-07-29
MY151455A (en) 2014-05-30
WO2007072153A2 (en) 2007-06-28
BRPI0620354A2 (pt) 2011-11-08
CA2634381A1 (en) 2007-06-28
IL191776A (en) 2013-03-24
HRP20130976T1 (hr) 2013-11-22
ECSP088558A (es) 2008-07-30
CU23751B7 (es) 2012-01-31
AP2008004506A0 (en) 2008-06-30
PL1979356T3 (pl) 2014-01-31

Similar Documents

Publication Publication Date Title
IL191776A0 (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
ZA200705628B (en) Pyrrolopyrazoles, potent kinase inhibitors
EG25264A (en) Biphenyl-n-(4-pyridyl) methylsulfonamides.
AP2402A (en) Amine derivatives.
IL190078A0 (en) Kinase inhibitors
EG25271A (en) Fungicidal combinations.
GB2424882B (en) Selective kinase inhibitors
SI2270008T1 (sl) 8-heteroaril-3-alkil-1,3-dihidro-imidazo(4,5-c)kinolin-2-oni kot inhibitorji PI-3 kinaz
IL192033A0 (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
AP2006003659A0 (en) Azabenzofuran substituted thioureas, inhibitors ofviral replication
ZA200805028B (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
AP2281A (en) Novel compounds.
PL1943243T3 (pl) Inhibitory kinazy
AP2337A (en) Motilide compounds.
AP2006003791A0 (en) 1-Heterocyclyl-1,5-dihydro-pyridoÄ3,2-BÜindol-2-ones
ZA200804667B (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
NL1031384A1 (nl) Gesubstitueerde aryl-1,4-pyrazinederivaten.
GB0505823D0 (en) Boardmate, boardmate adjustable
GB0504761D0 (en) Alfatie, Coliawel, Omaatie
ITRM20050033U1 (it) Semicabina per fumatori.
ITTO20050072U1 (it) Armadio-espositore, particolarmente per tabaccherie
ZA200803287B (en) Kinase inhibitors
IL189985A0 (en) Kinase inhibitors
CY2449B1 (en) Multiple srengthened carton.
PL378279A1 (pl) Układ do osuszania gazów zwłaszcza dla komór klimatycznych